Skin Medication Matrix Targets Venous Leg Ulcer Healing in New USA Clinical Trial

Share Article

Qualified participants will receive all trial related care and financial compensation for time and travel. No insurance is required.

News Image
The company, Factor Therapeutics Limited (ASX:FTT), previously ran a 53-patient trial where one-third of the ulcers healed in 12 weeks, with another half reducing in size by at least 70 per cent.

The effectiveness of a new wound healing skin medication for venous leg ulcers is now being assessed in clinical trials in the United States. (clinicaltrials.gov : NCT02973893)

To find out more about this clinical trial please talk to your nurse or physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and discuss your condition with one of the medical team.

The new treatment, VF001-DP, is a synthetic skin medication that attaches to the base of the ulcer and creates a microscopic scaffold matrix which encourages the body’s skin cells to move into the wound and regrow skin layers.

Venous ulcers account for 70%–90% of ulcers found on the lower leg, and cost the health system $3.5 billion each year.

Up to one-third of all patients with venous ulcers have recurring wounds, some up to four or more times.

Most sufferers are over 40 years old and are cared for in more than 1,000 out-patient wound care centers in the United States.

The clinical trial, VF00102, is open to 168 people over the age of 18 with non-healing venous ulcers who meet the eligibility criteria – these include:
1. a small ulcer (approx. size of a Dime) that has been there for more than 6 months; or
2. a larger one that has been there for less than 6 months

The company, Factor Therapeutics Limited (ASX:FTT), previously ran a 53-patient trial where one-third of the ulcers healed in 12 weeks, with another half reducing in size by at least 70 per cent.

Participants will have a two-week screening period, then randomised patients will be treated weekly for 12 weeks, with a 12-week follow-up period. All patients enrolled in the study will also receive high quality standard care as part of the trial.

To find out more about this clinical trial please talk to your nurse or physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and discuss your condition with one of the medical team.

Qualified participants will receive all trial related care and financial compensation for time and travel. No insurance is required.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Media Contact
@TrialWire
since: 01/2016
Follow >